ExAblate® Family of Systems

The ExAblate® 2000 system was the first system to use the MR guided focused ultrasound technology that combines MRI – to visualize the body anatomy, plan the treatment and monitor treatment outcome in real time and high intensity focused ultrasound to thermally ablate tumors inside the body non-invasively. MR thermometry allows the physician to control and adjust the treatment in real time to ensure that the targeted tissue is treated and surrounding non targeted tissue is spared.

The ExAblate® 2000 received CE mark in 2002 and the Food and Drug Administration (FDA) approval in 2004 for the treatment of symptomatic uterine fibroids. ExAblate® 2000 received the European CE Mark for pain palliation of bone metastases in June 2007 and for adenomyosis in June 2010. This device has won numerous innovation awards and has been used to treat thousands of patients around the world. 


ExAblate® OR is a non-invasive Operating Room. The system incorporates interchangeable cradles for each application that are interfaced with the standard table. ExAblate OR offers both commercially approved and research treatment options for a multitude of clinical indications such as: uterine fibroids and adenomyosis*, breast cancer*, prostate cancer*, pain palliation of bone metastases* and various other indications. 



ExAblate® One is designed for women’s health needs, including the treatment of uterine fibroids, adenomyosis*, and breast cancer*. 



ExAblate® Neuro is designed for the non-invasive treatment of various brain disorders*.

* Not all applications are approved in all regions. Please consult your local representatives and read the product labeling specific for your region to determine approved indications for use.